Stem cell-based therapies for cancer treatment: Separating hope from hype

Nature Reviews Cancer

Volumn 14, Issue 10, 2014, Pages 683-691

  Stuckey, Daniel W ^a   Shah, Khalid ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NANOCARRIER; ONCOLYTIC VIRUS; DRUG CARRIER;

ANTINEOPLASTIC ACTIVITY; CANCER CELL DESTRUCTION; CANCER THERAPY; CELL ENCAPSULATION; CLINICAL TRIAL (TOPIC); DNA MODIFICATION; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; HEMATOPOIETIC STEM CELL; HUMAN; MESENCHYMAL STEM CELL; NEURAL STEM CELL; ONCOLYTIC VIROTHERAPY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; ANIMAL; ARTICLE; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PHYSIOLOGY; STEM CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG CARRIERS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84909992665     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3798     Document Type: Review

References (125)

1. Abbott, A. Leaked files slam stem-cell therapy. Nature 505, 139-140 (2014
2. Jones, B. J., & McTaggart, S. J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 36, 733-741 (2008
3. Bernardo, M. E., & Fibbe, W. E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13, 392-402 (2013
4. Milwid, J. M. et al. Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Mol. Ther. 22, 999-1007 (2014
5. Muraoka, K. et al. The high integration and differentiation potential of autologous neural stem cell transplantation compared with allogeneic transplantation in adult rat hippocampus. Exp. Neurol. 199, 311-327 (2006
6. Zhao, T., Zhang, Z. N., Rong, Z., & Xu, Y. Immunogenicity of induced pluripotent stem cells. Nature 474, 212-215 (2011
7. Eliopoulos, N., Stagg, J., Lejeune, L., Pommey, S., & Galipeau, J. Allogeneic marrow stromal cells are immune rejected by MHC class I-And class II-mismatched recipient mice. Blood 106, 4057-4065 (2005
8. Zangi, L. et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 27, 2865-2874 (2009
9. Schu, S. et al. Immunogenicity of allogeneic mesenchymal stem cells. J. Cell. Mol. Med. 16, 2094-2103 (2012
10. Ankrum, J. A., Ong, J. F., & Karp, J. M. Mesenchymal stem cells: immune evasive, not immune privileged. Nature Biotech. 32, 252-260 (2014
11. Aboody, K. S. et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA 97, 12846-12851 (2000
12. Brown, A. B. et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum. Gene Ther. 14, 1777-1785 (2003
13. Tang, Y. et al. In vivo tracking of neural progenitor cell migration to glioblastomas, Hum. Gene Ther. 14, 1247-1254 (2003
14. Yang, J. et al. Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model. Stem Cells 30, 1021-1029 (2012
15. Shah, K. et al. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann. Neurol. 57, 34-41 (2005
16. Gondi, C. S. et al. Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo. Neuro Oncol. 12, 453-465 (2010
17. Suarez-Alvarez, B., Lopez-Vazquez, A., & Lopez-Larrea, C. Mobilization and homing of hematopoietic stem cells. Adv. Exp. Med. Biol. 741, 152-170 (2012
18. Shi, M. et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica 92, 897-904 (2007
19. Wynn, R. F. et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104, 2643-2645 (2004
20. Park, S. A. et al. CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas. Int. J. Oncol. 38, 97-103 (2011
21. Guo, Y., Hangoc, G., Bian, H., Pelus, L. M., & Broxmeyer, H. E. SDF-1/CXCL12 enhances survival and chemotaxis of murine embryonic stem cells and production of primitive and definitive hematopoietic progenitor cells. Stem Cells 23, 1324-1332 (2005
22. Koizumi, S. et al. Migration of mouse-induced pluripotent stem cells to glioma-conditioned medium is mediated by tumor-Associated specific growth factors. Oncol. Lett. 2, 283-288 (2011
23. Kendall, S. E. et al. Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling. Stem Cells 26, 1575-1586 (2008
24. Vallabhaneni, K. C. et al. Urokinase receptor mediates mobilization, migration, and differentiation of mesenchymal stem cells. Cardiovasc. Res. 90, 113-121 (2011
25. Gutova, M. et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 26, 1406-1413 (2008
26. Schmidt, N. O. et al. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia 7, 623-629 (2005
27. Ho, I. A. et al. Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 27, 1366-1375 (2009
28. Motaln, H. et al. Human mesenchymal stem cells exploit the immune response mediating chemokines to impact the phenotype of glioblastoma. Cell Transplant 21, 1529-1545 (2012
29. Schichor, C. et al. Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Exp. Neurol. 234, 208-219 (2012
30. Qiao, L. et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 18, 500-507 (2008
31. Hu, Y. L. et al. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection. Mol. Pharm. 9, 2698-2709 (2012
32. Jo, J., Hong, S., Choi, W. Y., & Lee, D. R. Cell-penetrating peptide (CPP)-conjugated proteins is an efficient tool for manipulation of human mesenchymal stromal cells. Sci. Rep. 4, 4378 (2014
33. Stuckey, D. W., & Shah, K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol. Med. 19, 685-694 (2013
34. Sasportas, L. S. et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc. Natl Acad. Sci. USA 106, 4822-4827 (2009
35. van de Water, J. A. et al. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc. Natl Acad. Sci. USA 109, 16642-16647 (2012
36. Balyasnikova, I. V., Ferguson, S. D., Sengupta, S., Han, Y., & Lesniak, M. S. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS ONE 5, e9750 (2010
37. Ito, S. et al. Human neural stem cells transduced with IFN-? and cytosine deaminase genes intensify bystander effect in experimental glioma. Cancer Gene Ther. 17, 299-306 (2010
38. Studeny, M. et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-? delivery into tumors. Cancer Res. 62, 3603-3608 (2002
39. Ren, C. et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-? in a mouse prostate cancer lung metastasis model. Gene Ther. 15, 1446-1453 (2008
40. Dembinski, J. L. et al. Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy 15, 20-32 (2013
41. Ren, C. et al. Therapeutic potential of mesenchymal stem cells producing interferon-? in a mouse melanoma lung metastasis model. Stem Cells 26, 2332-2338 (2008
42. van Eekelen, M. et al. Human stem cells expressing novel TSP-1 variant have anti-Angiogenic effect on brain tumors. Oncogene 29, 3185-3195 (2010
43. Kim, S. K. et al. PEX-producing human neural stem cells inhibit tumor growth in a mouse glioma model. Clin. Cancer Res. 11, 5965-5970 (2005
44. Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268-276 (2013
45. Gao, P., Ding, Q., Wu, Z., Jiang, H., & Fang, Z. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett. 290, 157-166 (2010
46. Seo, S. H. et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 18, 488-495 (2011
47. Ryu, C. H. et al. Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum. Gene Ther. 22, 733-743 (2011
48. Hong, X., Miller, C., Savant-Bhonsale, S., & Kalkanis, S. N. Antitumor treatment using interleukin-12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery 64, 1139-1146; discussion 1146-1147 (2009
49. Xu, G. et al. Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol. Int. 33, 466-474 (2009
50. Kosaka, H. et al. Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. Cancer Gene Ther. 19, 572-578 (2012
51. Zhao, Y. et al. Targeted suicide gene therapy for glioma using human embryonic stem cell-derived neural stem cells genetically modified by baculoviral vectors. Gene Ther. 19, 189-200 (2012
52. Aboody, K. S. et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci. Transl. Med. 5,184ra59 (2013
53. Altaner, C. et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int. J. Cancer 134, 1458-1465 (2014
54. Kim, S. K. et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin. Cancer Res. 12, 5550-5556 (2006
55. Martinez-Quintanilla, J. et al. Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells 31, 1706-1714 (2013
56. Ryu, C. H. et al. Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma. Biochem. Biophys. Res. Commun. 421, 585-590 (2012
57. Lee, W. Y. et al. Immortalized human fetal bone marrow-derived mesenchymal stromal cell expressing suicide gene for anti-tumor therapy in vitro and in vivo. Cytotherapy 15, 1484-1497 (2013
58. Kim, K. Y., Kim, S. U., Leung, P. C., Jeung, E. B., & Choi, K. C. Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci. 101, 955-962 (2010
59. Hong, S. H. et al. Human neural stem cells expressing carboxyl esterase target and inhibit tumor growth of lung cancer brain metastases. Cancer Gene Ther. 20, 678-682 (2013
60. Gutova, M. et al. Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma. Gene Ther. 20, 143-150 (2013
61. Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv. Drug. Deliv. Rev. 66, 2-25 (2014
62. Roger, M. et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 31, 8393-8401 (2010
63. Auffinger, B. et al. Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget 4, 378-396 (2013
64. Li, L. et al. Silica nanorattle-doxorubicin-Anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano 5, 7462-7470 (2011
65. Duchi, S. et al. Mesenchymal stem cells as delivery vehicle of porphyrin loaded nanoparticles: effective photoinduced in vitro killing of osteosarcoma. J. Control Release 168, 225-237 (2013
66. Schnarr, K. et al. Gold nanoparticle-loaded neural stem cells for photothermal ablation of cancer. Adv. Healthc. Mater. 2, 976-982 (2013
67. Rachakatla, R. S. et al. Attenuation of mouse melanoma by A/C magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano 4, 7093-7104 (2010
68. Aghi, M., & Martuza, R. L. Oncolytic viral therapies-the clinical experience. Oncogene 24, 7802-7816 (2005
69. Garcia-Castro, J. et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther. 17, 476-483 (2010
70. Komarova, S., Kawakami, Y., Stoff-Khalili, M. A., Curiel, D. T., & Pereboeva, L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 5, 755-766 (2006
71. Kranzler, J., Tyler, M. A., Sonabend, A. M., Ulasov, I. V., & Lesniak, M. S. Stem cells as delivery vehicles for oncolytic adenoviral virotherapy. Curr. Gene Ther. 9, 389-395 (2009
72. Ahmed, A. U. et al. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-Adenoviral immune response in the cotton rat model. Mol. Ther. 18, 1846-1856 (2010
73. Stoff-Khalili, M. A. et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res. Treat. 105, 157-167 (2007
74. Sonabend, A. M. et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26, 831-841 (2008
75. Yong, R. L. et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 69, 8932-8940 (2009
76. Ahmed, A. U. et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol. Pharm. 8, 1559-1572 (2011
77. Mader, E. K. et al. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J. Transl. Med. 11, 20 (2013
78. Ong, H. T. et al. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J. Hepatol 59, 999-1006 (2013
79. Hoffmann, D., & Wildner, O. Comparison of herpes simplex virus-And conditionally replicative adenovirus-based vectors for glioblastoma treatment. Cancer Gene Ther. 14, 627-639 (2007
80. Markert, J. M. et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-And post-tumor resection for recurrent GBM. Mol. Ther. 17, 199-207 (2009
81. Harrow, S. et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 11, 1648-1658 (2004
82. Papanastassiou, V. et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 9, 398-406 (2002
83. Duebgen, M. et al. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J. Natl Cancer Inst. 106, dju090 (2014
84. Torikai, H. et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122, 1341-1349 (2013
85. Sander, J. D., & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotech. 32, 347-355 (2014
86. Mussolino, C., & Cathomen, T. TALE nucleases: tailored genome engineering made easy. Curr. Opin. Biotechnol. 23, 644-650 (2012
87. Rong, Z. et al. An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell 14, 121-130 (2014
88. Ankrum, J. A. et al. Engineering cells with intracellular agent-loaded microparticles to control cell phenotype. Nature Protoc. 9, 233-245 (2014
89. Sarkar, D., Ankrum, J. A., Teo, G. S., Carman, C. V., & Karp, J. M. Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms. Biomaterials 32, 3053-3061 (2011
90. Honeth, G., Staflin, K., Kalliomaki, S., Lindvall, M., & Kjellman, C. Chemokine-directed migration of tumor-inhibitory neural progenitor cells towards an intracranially growing glioma. Exp. Cell Res. 312, 1265-1276 (2006
91. Kim, D. S. et al. Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev. 18, 511-519 (2009
92. Ratajczak, M. Z. et al. A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients. Leukemia 26, 63-72 (2012
93. Pulukuri, S. M., Gorantla, B., Dasari, V. R., Gondi, C. S., & Rao, J. S. Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells. Mol. Cancer Res. 8, 1074-1083 (2010
94. Zielske, S. P., Livant, D. L., & Lawrence, T. S. Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int. J. Radiat. Oncol. Biol. Phys. 75, 843-853 (2009
95. Klopp, A. H. et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 67, 11687-11695 (2007
96. Meacham, C. E., & Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328-337 (2013
97. Hanahan, D. Rethinking the war on cancer. Lancet 383, 558-563 (2014
98. Yi, B. R. et al. Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-? against ductal breast cancer cells in cellular and xenograft models. Stem Cell Res. 12, 36-48 (2014
99. Yan, C. et al. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma. Mol. Pharm. 10, 142-151 (2013
100. Du, W., Uslar, L., Sevala, S., & Shah, K. Targeting c-Met receptor overcomes TRAIL-resistance in brain tumors. PLoS ONE 9, e95490 (2014
101. Kim, S. M. et al. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl. Med. 3, 172-182 (2014
102. Tobias, A. L. et al. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl. Med. 2, 655-666 (2013
103. Reitz, M. et al. Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem Cells Transl. Med. 1, 866-873 (2012
104. Balyasnikova, I. V. et al. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol. Ther. 22, 140-148 (2014
105. Burdick, J. A., & Prestwich, G. D. Hyaluronic acid hydrogels for biomedical applications. Adv. Mater. 23, H41-H56 (2011
106. Hansen, K. et al. A 3-dimensional extracellular matrix as a delivery system for the transplantation of glioma-targeting neural stem/progenitor cells. Neuro Oncol. 12, 645-654 (2010
107. Goren, A., Dahan, N., Goren, E., Baruch, L., & Machluf, M. Encapsulated human mesenchymal stem cells: a unique hypoimmunogenic platform for long-term cellular therapy. FASEB J. 24, 22-31 (2010
108. Rihova, B. Immunocompatibility and biocompatibility of cell delivery systems. Adv. Drug Deliv. Rev. 42, 65-80 (2000
109. Reagan, M. R. et al. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. J. Breast Cancer 15, 273-282 (2012
110. Kauer, T. M., Figueiredo, J. L., Hingtgen, S., & Shah, K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nature Neurosci. 15, 197-204 (2012
111. Menon, L. G. et al. Imaging of human mesenchymal stromal cells: homing to human brain tumors. J. Neurooncol. 107, 257-267 (2012
112. Thu, M. S. et al. Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS ONE 4, e7218 (2009
113. Chien, L. Y. et al. In vivo magnetic resonance imaging of cell tropism, trafficking mechanism, and therapeutic impact of human mesenchymal stem cells in a murine glioma model. Biomaterials 32, 3275-3284 (2011
114. Gutova, M. et al. Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use. Stem Cells Transl. Med. 2, 766-775 (2013
115. Hasenbach, K. et al. Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography. Neuro Oncol. 14, 471-481 (2012
116. Sweeney, T. J. et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc. Natl Acad. Sci. USA 96, 12044-12049 (1999
117. Bianco, P. et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nature Med. 19, 35-42 (2013
118. Garraway, L. A., & Lander, E. S. Lessons from the cancer genome. Cell 153, 17-37 (2013
119. Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563 (2007
120. Yang, T. et al. Activation of mesenchymal stem cells by macrophages prompts human gastric cancer growth through NF-?B pathway. PLoS ONE 9, e97569 (2014
121. Rowan, B. G. et al. Human adipose tissue-derived stromal/stem cells promote migration and early metastasis of triple negative breast cancer xenografts. PLoS ONE 9, e89595 (2014
122. Amariglio, N. et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 6, e1000029 (2009
123. Rosland, G. V. et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 69, 5331-5339 (2009
124. Lee, A. S., Tang, C., Rao, M. S., Weissman, I. L., & Wu, J. C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nature Med. 19, 998-1004 (2013
125. Ring, K. L. et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 11, 100-109 (2012).